Related Experiment Video
Updated: Jul 13, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Deoxybenzoins are novel potent selective estrogen receptor modulators
Zoi Papoutsi1, Eva Kassi, Nikolas Fokialakis
1Department of Biological Chemistry, Medical School, University of Athens, 75 Mikras Asias Street, Goudi 11527, Athens, Greece.
Steroids
|July 31, 2007
Summary
Two novel deoxybenzoins were tested for estrogen receptor activity. Compound 2 shows potential as a selective estrogen receptor modulator for hormone replacement therapy due to its varied effects on different cell types.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Deoxybenzoins are plant-derived compounds structurally related to isoflavones.
- Estrogen receptors (ERalpha and ERbeta) play crucial roles in various physiological processes.
- Understanding the interaction of novel compounds with estrogen receptors is vital for therapeutic development.
Purpose of the Study:
- To evaluate the estrogenic and anti-estrogenic activities of two synthesized deoxybenzoins (Compound 1 and Compound 2).
- To assess their effects on specific protein modulation, osteoblast mineralization, and cancer cell viability.
- To investigate their potential as selective estrogen receptor modulators (SERMs).
Main Methods:
- In vitro assays using HeLa cells co-transfected with ER-expression vectors and a luciferase reporter gene.
- Western blot analysis to measure IGFBP-3 and pS2 protein levels in MCF-7 cells.
- Osteoblast mineralization assays and cell viability assessments in endometrial and breast cancer cell lines.
- Molecular modeling including docking and binding energy calculations using Macromodel 6.5.
Main Results:
- Compound 1 exhibited estrogenic activity via ERbeta but not ERalpha.
- Compound 2 acted as an ERalpha agonist and ERbeta antagonist.
- Both compounds increased IGFBP-3 levels; Compound 2 induced osteoblast mineralization.
- Compound 1 enhanced MCF-7 cell viability and pS2 levels, while Compound 2 inhibited viability.
Conclusions:
- Compound 2 demonstrates selective estrogen receptor modulation, acting as an agonist in osteoblasts and an antagonist in breast cancer cells.
- Its varied effects suggest potential applications in hormone replacement therapy.
- Further research into Compound 2's therapeutic potential is warranted based on its selective activity profile.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...